TD Cowen Bullish on KalVista Pharmaceuticals, Inc. (KALV) Ahead of Q4 Results

Core Insights - KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is recognized as one of the 20 Best Biotech Stocks Under $20 to buy now, ranking twelfth on the list [1] - Analysts from TD Cowen and H.C. Wainwright have raised their price targets for KALV, indicating strong confidence in the company's future performance [2][1] Analyst Ratings - TD Cowen analyst Stacy Ku increased the price target for KALV from $30 to $35 while maintaining a Buy rating, following an update to the financial model ahead of the fourth-quarter results [1] - H.C. Wainwright analyst Andrew Fein raised the price target from $27 to $37, also maintaining a Buy rating, citing confidence from the company's fiscal 2025 EKTERLY revenue [2] Company Overview - KalVista Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small-molecule protease inhibitors for rare diseases, including hereditary angioedema and diabetic macular edema [3] - The company aims to provide oral and targeted therapies to enhance patient outcomes and quality of life [3]